Australasian Leukaemia and Lymphoma Group National Blood Cancer Registry

Not Applicable

Recruiting

• Conditions: Suspected or Known or Diagnosed Blood Cancer; Cancer - Leukaemia - Acute leukaemia; Public Health - Health service research; Cancer - Lymphoma (non Hodgkin's lymphoma) - Low grade lymphoma

• Registration Number: ACTRN12612000337875
• Lead Sponsor: Australasian Leukaemia and Lymphoma Group

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2012-03-23
• Last Update Posted: 8 April 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 2000

Inclusion Criteria

1. Male or female with a suspected, or known, or diagnosed blood cancer
2. Aged 15 and over
3. Has provided written informed consent

Exclusion Criteria

nil

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
To establish a common registration platform for patients with suspected blood cancer in Australia and New Zealand.[ mid 2012 onwards];To facilitate the participation of patients with blood cancers in ALLG clinical trials and ensure patients are enrolled in the trial most appropriate to their diagnosis.[ mid 2012 onwards];To improve the efficiency of data management for ALLG clinical trials by centralising data collection at baseline.[ mid 2012 onwards]

Secondary Outcome Measures

Name	Time	Method
To promote a mechanism for centralised review of cytogenetic and molecular reporting where applicable.[ mid 2012 onwards];To facilitate collection of blood cancer samples linked to clinical diagnostic, prognostic, treatment and outcome data.[ mid 2012 onwards];To facilitate sample collection and review of bone marrow of patients with suspected relapsed blood cancer.[ mid 2012 onwards];To develop the platform to provide information about the clinical profile, cytogenetic and molecular characteristics and treatment outcomes of patients with blood cancer in Australia and New Zealand.[ mid 2012 onwards];To gain better understanding of disease progression and patterns of care for patients with blood cancers not participating in clinical trials.[ mid 2012 onwards];To inform and facilitate design of future ALLG studies for patients with blood cancer.[ mid 2012 onwards]